Search

everythinglearnresearchcommunity

for

Search:↓

Different drug doses approved in Japan and the U.S. are not mainly due to different clinical responses, and ethnic factors should be considered in setting drug doses.

Cancer survivors often experience worse skin problems from treatment than expected, and working with dermatologists could help improve their condition.

The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

Finasteride has a higher risk of reproductive side effects than minoxidil.

Scalp cooling is the most effective FDA-approved method to prevent chemotherapy-induced hair loss, but more research is needed for other treatments.

Low-level laser therapy is the most effective for hair loss, but other treatments also show promise.

Minoxidil and finasteride are the main FDA-approved treatments for hair loss, with other methods showing promise but lacking strong evidence.

Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.

Reporter characteristics affect detection of hair loss from cancer therapy.

Six African American women experienced hair loss after switching to a new HIV medication.

The document concludes that there are various treatments for different types of alopecia, but more research is needed for evidence-based treatments.

Low-level laser therapy is the most supported treatment for hair loss, but other methods show promise.

LLLT helps treat hair loss by increasing blood flow, reducing inflammation, and stimulating growth factors.

Some men experience persistent sexual, neurological, and psychological symptoms after stopping finasteride, but evidence of permanent damage is inconclusive.

Extracellular vesicles show potential in dermatology, but more research is needed for validation.

Maintaining sexual health after menopause is possible with patient approaches, hormone supplements, and therapy, despite needing more research.

JAK inhibitors are effective for treating moderate-to-severe alopecia areata.

Drugs targeting the Androgen Receptor are effective for treating prostate cancer and other androgen-related conditions.

Exosomes from platelet-rich plasma may help heal wounds but need more research for hair growth and skin use.

Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.

Targeting the Smoothened receptor shows promise for treating certain cancers.

The document concludes that new treatments are needed to better manage acne and reduce side effects related to current therapies.

High-content screening is useful for finding new treatments for rare diseases and has led to FDA-approved drugs.

Testosterone therapy can help improve sexual desire and function in postmenopausal women but may cause side effects and is not FDA-approved for this use.

Mesotherapy lacks strong evidence for effectiveness and safety, and its ingredients are not FDA-approved for subcutaneous use.

The FDA approved the first gene therapy for a blood disorder after overcoming early challenges and demonstrating patient benefits.

Deoxycholic acid is FDA-approved for reducing submental fat, but its mechanisms are not fully understood.

Scalp cooling is the only FDA-approved method to prevent hair loss from chemotherapy, but other treatments like minoxidil and PRP are being tested.